Six-Month Prospective Life Charting of Mood Symptoms with Lamotrigine Monotherapy Versus Placebo in Rapid Cycling Bipolar Disorder

Joseph F. Goldberg, Charles L. Bowden, Joseph R. Calabrese, Terence A. Ketter, Rebekkah S. Dann, Mark A Frye, Trisha Suppes, Robert M. Post

Research output: Contribution to journalArticle

27 Citations (Scopus)

Abstract

Background: Fluctuations in mood are quintessential features of bipolar disorder; however, previous studies have seldom examined the extent to which pharmacotherapies for bipolar disorder may reduce or ameliorate daily or weekly mood variability. The anticonvulsant lamotrigine has demonstrated efficacy for relapse prevention in bipolar disorder, but its possible mood-stabilizing properties on a day-to-day or week-to-week basis have not previously been investigated. Methods: Weekly mood shifts were examined over 26 weeks using patients' self-reported prospective Life Chart Method (LCM) data obtained as part of a previously reported randomized relapse prevention comparison of lamotrigine monotherapy or placebo in 182 bipolar patients with DSM-IV rapid cycling. Generalized estimating equation (GEE) analyses were used to compare treatment arms for subjects who achieved euthymia across weeks. Results: After adjusting for potential confounding factors, a final GEE model revealed that subjects taking lamotrigine were 1.8 times more likely than those taking placebo to achieve euthymia, as measured by LCM, at least once per week over 6 months (95% confidence interval [CI] = 1.03-3.13). Subjects taking lamotrigine had an increase of .69 more days per week euthymic as compared with those taking placebo (p = .014). Conclusions: Achievement of euthymia across weeks represents a novel paradigm shift in gauging the mood-stabilizing properties of a psychotropic agent. The present findings demonstrate the utility of the prospective Life Chart Method for assessing longitudinal mood stability during randomized clinical trials for bipolar disorder. The results lend support to the potential mood-stabilizing properties of lamotrigine monotherapy for bipolar disorder.

Original languageEnglish (US)
Pages (from-to)125-130
Number of pages6
JournalBiological Psychiatry
Volume63
Issue number1
DOIs
StatePublished - Jan 1 2008

Fingerprint

Bipolar Disorder
Placebos
Secondary Prevention
lamotrigine
Diagnostic and Statistical Manual of Mental Disorders
Anticonvulsants
Randomized Controlled Trials
Confidence Intervals
Drug Therapy

Keywords

  • Bipolar disorder
  • lamotrigine
  • Life Chart Method
  • mood stabilizer
  • rapid cycling

ASJC Scopus subject areas

  • Biological Psychiatry

Cite this

Six-Month Prospective Life Charting of Mood Symptoms with Lamotrigine Monotherapy Versus Placebo in Rapid Cycling Bipolar Disorder. / Goldberg, Joseph F.; Bowden, Charles L.; Calabrese, Joseph R.; Ketter, Terence A.; Dann, Rebekkah S.; Frye, Mark A; Suppes, Trisha; Post, Robert M.

In: Biological Psychiatry, Vol. 63, No. 1, 01.01.2008, p. 125-130.

Research output: Contribution to journalArticle

Goldberg, Joseph F. ; Bowden, Charles L. ; Calabrese, Joseph R. ; Ketter, Terence A. ; Dann, Rebekkah S. ; Frye, Mark A ; Suppes, Trisha ; Post, Robert M. / Six-Month Prospective Life Charting of Mood Symptoms with Lamotrigine Monotherapy Versus Placebo in Rapid Cycling Bipolar Disorder. In: Biological Psychiatry. 2008 ; Vol. 63, No. 1. pp. 125-130.
@article{6d2979dd0fda48efa3446fefbf699be0,
title = "Six-Month Prospective Life Charting of Mood Symptoms with Lamotrigine Monotherapy Versus Placebo in Rapid Cycling Bipolar Disorder",
abstract = "Background: Fluctuations in mood are quintessential features of bipolar disorder; however, previous studies have seldom examined the extent to which pharmacotherapies for bipolar disorder may reduce or ameliorate daily or weekly mood variability. The anticonvulsant lamotrigine has demonstrated efficacy for relapse prevention in bipolar disorder, but its possible mood-stabilizing properties on a day-to-day or week-to-week basis have not previously been investigated. Methods: Weekly mood shifts were examined over 26 weeks using patients' self-reported prospective Life Chart Method (LCM) data obtained as part of a previously reported randomized relapse prevention comparison of lamotrigine monotherapy or placebo in 182 bipolar patients with DSM-IV rapid cycling. Generalized estimating equation (GEE) analyses were used to compare treatment arms for subjects who achieved euthymia across weeks. Results: After adjusting for potential confounding factors, a final GEE model revealed that subjects taking lamotrigine were 1.8 times more likely than those taking placebo to achieve euthymia, as measured by LCM, at least once per week over 6 months (95{\%} confidence interval [CI] = 1.03-3.13). Subjects taking lamotrigine had an increase of .69 more days per week euthymic as compared with those taking placebo (p = .014). Conclusions: Achievement of euthymia across weeks represents a novel paradigm shift in gauging the mood-stabilizing properties of a psychotropic agent. The present findings demonstrate the utility of the prospective Life Chart Method for assessing longitudinal mood stability during randomized clinical trials for bipolar disorder. The results lend support to the potential mood-stabilizing properties of lamotrigine monotherapy for bipolar disorder.",
keywords = "Bipolar disorder, lamotrigine, Life Chart Method, mood stabilizer, rapid cycling",
author = "Goldberg, {Joseph F.} and Bowden, {Charles L.} and Calabrese, {Joseph R.} and Ketter, {Terence A.} and Dann, {Rebekkah S.} and Frye, {Mark A} and Trisha Suppes and Post, {Robert M.}",
year = "2008",
month = "1",
day = "1",
doi = "10.1016/j.biopsych.2006.12.031",
language = "English (US)",
volume = "63",
pages = "125--130",
journal = "Biological Psychiatry",
issn = "0006-3223",
publisher = "Elsevier USA",
number = "1",

}

TY - JOUR

T1 - Six-Month Prospective Life Charting of Mood Symptoms with Lamotrigine Monotherapy Versus Placebo in Rapid Cycling Bipolar Disorder

AU - Goldberg, Joseph F.

AU - Bowden, Charles L.

AU - Calabrese, Joseph R.

AU - Ketter, Terence A.

AU - Dann, Rebekkah S.

AU - Frye, Mark A

AU - Suppes, Trisha

AU - Post, Robert M.

PY - 2008/1/1

Y1 - 2008/1/1

N2 - Background: Fluctuations in mood are quintessential features of bipolar disorder; however, previous studies have seldom examined the extent to which pharmacotherapies for bipolar disorder may reduce or ameliorate daily or weekly mood variability. The anticonvulsant lamotrigine has demonstrated efficacy for relapse prevention in bipolar disorder, but its possible mood-stabilizing properties on a day-to-day or week-to-week basis have not previously been investigated. Methods: Weekly mood shifts were examined over 26 weeks using patients' self-reported prospective Life Chart Method (LCM) data obtained as part of a previously reported randomized relapse prevention comparison of lamotrigine monotherapy or placebo in 182 bipolar patients with DSM-IV rapid cycling. Generalized estimating equation (GEE) analyses were used to compare treatment arms for subjects who achieved euthymia across weeks. Results: After adjusting for potential confounding factors, a final GEE model revealed that subjects taking lamotrigine were 1.8 times more likely than those taking placebo to achieve euthymia, as measured by LCM, at least once per week over 6 months (95% confidence interval [CI] = 1.03-3.13). Subjects taking lamotrigine had an increase of .69 more days per week euthymic as compared with those taking placebo (p = .014). Conclusions: Achievement of euthymia across weeks represents a novel paradigm shift in gauging the mood-stabilizing properties of a psychotropic agent. The present findings demonstrate the utility of the prospective Life Chart Method for assessing longitudinal mood stability during randomized clinical trials for bipolar disorder. The results lend support to the potential mood-stabilizing properties of lamotrigine monotherapy for bipolar disorder.

AB - Background: Fluctuations in mood are quintessential features of bipolar disorder; however, previous studies have seldom examined the extent to which pharmacotherapies for bipolar disorder may reduce or ameliorate daily or weekly mood variability. The anticonvulsant lamotrigine has demonstrated efficacy for relapse prevention in bipolar disorder, but its possible mood-stabilizing properties on a day-to-day or week-to-week basis have not previously been investigated. Methods: Weekly mood shifts were examined over 26 weeks using patients' self-reported prospective Life Chart Method (LCM) data obtained as part of a previously reported randomized relapse prevention comparison of lamotrigine monotherapy or placebo in 182 bipolar patients with DSM-IV rapid cycling. Generalized estimating equation (GEE) analyses were used to compare treatment arms for subjects who achieved euthymia across weeks. Results: After adjusting for potential confounding factors, a final GEE model revealed that subjects taking lamotrigine were 1.8 times more likely than those taking placebo to achieve euthymia, as measured by LCM, at least once per week over 6 months (95% confidence interval [CI] = 1.03-3.13). Subjects taking lamotrigine had an increase of .69 more days per week euthymic as compared with those taking placebo (p = .014). Conclusions: Achievement of euthymia across weeks represents a novel paradigm shift in gauging the mood-stabilizing properties of a psychotropic agent. The present findings demonstrate the utility of the prospective Life Chart Method for assessing longitudinal mood stability during randomized clinical trials for bipolar disorder. The results lend support to the potential mood-stabilizing properties of lamotrigine monotherapy for bipolar disorder.

KW - Bipolar disorder

KW - lamotrigine

KW - Life Chart Method

KW - mood stabilizer

KW - rapid cycling

UR - http://www.scopus.com/inward/record.url?scp=36849045846&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=36849045846&partnerID=8YFLogxK

U2 - 10.1016/j.biopsych.2006.12.031

DO - 10.1016/j.biopsych.2006.12.031

M3 - Article

C2 - 17543894

AN - SCOPUS:36849045846

VL - 63

SP - 125

EP - 130

JO - Biological Psychiatry

JF - Biological Psychiatry

SN - 0006-3223

IS - 1

ER -